Hence, in the present study, we have built on our previous findings to show that the selective PAR2 activator, AC-264613 (AC; Gardell et al. 2008; Barry et al. 2010), crosses the blood–brain barrier (BBB) and induces behavioural changes similar to those observed in depression-like behaviour. Here, F2RL1 is linked to depressive symptom measurement.